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Abstract: Anti-apoptotic Bcl-2-family members are frequently dysregulated in both blood and solid
cancers, contributing to their survival despite ongoing oncogenic stress. Yet, such cancer cells often
are highly dependent on Bcl-2 for their survival, a feature that is exploited by so-called BH3-mimetic
drugs. Venetoclax (ABT-199) is a selective BH3-mimetic Bcl-2 antagonist that is currently used in the
clinic for treatment of chronic lymphocytic leukemia patients. Unfortunately, venetoclax resistance
has already emerged in patients, limiting the therapeutic success. Here, we examined strategies to
overcome venetoclax resistance. Therefore, we used two diffuse large B-cell lymphoma (DLBCL) cell
lines, Riva WT and venetoclax-resistant Riva (VR). The latter was obtained by prolonged culturing in
the presence of venetoclax. We report that Riva VR cells did not become more sensitive to BIRD-2,
a peptide targeting the Bcl-2 BH4 domain, and established cross-resistance towards BDA-366, a
putative BH4-domain antagonist of Bcl-2. However, we found that Bcl-XL, another Bcl-2-family
protein, is upregulated in Riva VR, while Mcl-1 expression levels are not different in comparison
with Riva WT, hinting towards an increased dependence of Riva VR cells to Bcl-XL. Indeed, Riva
VR cells could be resensitized to venetoclax by A-1155463, a selective BH3 mimetic Bcl-XL inhibitor.
This is underpinned by siRNA experiments, demonstrating that lowering Bcl-XL-expression levels
also augmented the sensitivity of Riva VR cells to venetoclax. Overall, this work demonstrates that
Bcl-XL upregulation contributes to acquired resistance of DLBCL cancer cells towards venetoclax and
that antagonizing Bcl-XL can resensitize such cells towards venetoclax.
Keywords: Ca2+ signaling; ABT-199; BH3 mimetics; Bcl-2; Bcl-XL; IP3 receptors
1. Introduction
The Bcl-2 protein family regulates the onset of apoptosis by critically controlling mitochondrial
outer membrane permeabilization [1,2]. The balance between pro-apoptotic (such as BAX/BAK and
BH3-only proteins) and anti-apoptotic (such as Bcl-2, Bcl-XL and Mcl-1) family members is a crucial
factor in determining cell death and survival [3]. Anti-apoptotic Bcl-2 protein family members are
Biomolecules 2020, 10, 1081; doi:10.3390/biom10071081 www.mdpi.com/journal/biomolecules
Biomolecules 2020, 10, 1081 2 of 13
upregulated in various cancers, e.g., chronic lymphocytic leukemia (CLL) [4], diffuse large B-cell
lymphoma (DLBCL) [4], but also solid tumors such as prostate cancer [5]. This enables cancer
cells to survive despite pro-apoptotic, oncogenic stress [6]. A crucial feature of anti-apoptotic Bcl-2
family members is their hydrophobic cleft, consisting of Bcl-2 homology (BH) domains 1, 2 and
3 [1]. The hydrophobic groove interacts with the BH3 domain of pro-apoptotic Bcl-2 family members,
thereby sequestering them and inhibiting their pro-apoptotic function [1,7]. Venetoclax is the first
clinically used BH3 mimetic to treat relapsed CLL cancer patients [8–10] and does so by occupying
the hydrophobic groove of the anti-apoptotic protein Bcl-2 [7,11]. This prevents the sequestration of
pro-apoptotic Bcl-2 family proteins, often upregulated due to oncogenic stress [12] and tips cancer
cells “addicted” to Bcl-2 for survival over the edge of apoptosis [13]. Ever since its launch in the clinic,
venetoclax has been a precision medicine with great potential and success [11]. While initially it was
approved as a therapy for CLL, current research focuses on its use in other types of cancer such as
DLBCL, follicular lymphoma, myeloma and acute myeloid leukemia [11,14,15].
However, as is often the case with targeted therapies, some cancers developed resistance against
venetoclax, rendering it ineffective in long-term treatments to cure patients of cancer [11]. To understand
the mechanisms underlying venetoclax resistance better and potentially exploit them, we decided to
investigate whether venetoclax-resistant cells become reliant on the antagonizing role of Bcl-2 role at
the endoplasmic reticulum (ER) [16,17]. The ER serves as the main intracellular Ca2+ storage organelle
that controls a plethora of cell functions including cell survival [18]. During the last decades, several
Bcl-2-family members have been identified at the ER where they functionally impact Ca2+ homeostasis
and dynamics [19,20]. Bcl-2 directly targets IP3Rs via its BH4 domain and inhibits Ca2+ flux through
the channel, preventing apoptosis [21–23]. Targeting Bcl-2 at the ER can be achieved through Bcl-2-IP3R
disrupter 2 (BIRD-2) [24–26]. This is a decoy peptide for Bcl-2 based on its binding sequence in the
central, regulatory domain of the inositol 1,4,5-trisphosphate receptor (IP3R) [17,23,27]. BIRD-2 can
kill several Bcl-2-dependent cancer cell types, including primary CLL cells and DLBCL cell lines, by
provoking intracellular Ca2+ overload [26–28]. At the molecular level, we found that the combined
upregulation of the type 2 IP3R (IP3R2 isoform) in combination with ongoing chronic IP3 signaling
downstream of the chronically/tonically active B-cell receptor rendered cancer cells sensitive to BIRD-2
exposure [28,29].
Moreover, previous work from our team revealed that there is a reciprocal correlation between
venetoclax sensitivity and BIRD-2 sensitivity, i.e., cancer cells that were more sensitive to venetoclax
were more resistant to BIRD-2 and vice versa [30]. Hence, in this work, we wished to examine whether
cancer cells that have become resistant to venetoclax were more sensitive to BIRD-2. Therefore, we
compared BIRD-2 sensitivity in an isogenic cell model with acquired venetoclax resistance. This was
achieved by culturing the DLBCL cell line Riva in conditions of chronic exposure to venetoclax. Here,
we compared the sensitivity towards BIRD-2 between naïve Riva cells (Riva WT) and isogenic Riva
cells with acquired resistance towards venetoclax (Riva VR).
We reported that Riva VR do not develop increased sensitivity towards BIRD-2 compared to
their naïve counterparts. Consistently, we did not see an upregulation of the IP3R. In addition, we
found that Bcl-XL upregulation is at least in part responsible for the resistance to venetoclax, while
Mcl-1-expression levels appeared unaltered. Finally, we observed cross-resistance towards BDA-366, a
molecule proposedly targeting the BH4 domain of Bcl-2 [31].
2. Materials and Methods
2.1. Cell Culture and Chemicals
Riva WT and VR were grown in RPMI (Gibco/Invitrogen, Merelbeke, Belgium) supplemented
with 2 mM glutamax, 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin and 100 µg/mL
streptomycin (100× Pen/Strep, Gibco/Invitrogen, Merelbeke, Belgium) at 37 ◦C and 5% CO2. Resistance
to venetoclax was achieved by culturing Riva cells in increasing concentrations of venetoclax over more
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than three months. This selection started with low nanomolar concentrations of venetoclax (1–10 nM)
and concentrations were stepwise increased up to 300 nM when more than 30% of cells survived
the selection. Survival of cells was monitored using AnnexinV-FITC staining and flow cytometry
twice a week. Venetoclax was purchased from Active Biochem (Kowloon, Hong Kong). Cells were
seeded 24 h before being used in experiments at a density of 250,000/mL. BIRD-2 peptide (sequence:
RKKRRQRRRGGNVYTEIKCNSLLPLAAIVRV) was purchased from LifeTein (South Plainfield, NJ,
USA) with a purity of >85%. BDA-366 was purchased from BioVision (Milpitas, CA, USA). Both S63845
and A-1155463 were purchased from Selleckchem (Munich, Germany).
2.2. Flow Cytometry: Apoptosis Assay
Riva WT and VR cells were treated for 24 h with venetoclax, BIRD-2, BDA-366, S63845 or
A-1155463 or a combination of these. Subsequently, cells were pelleted by centrifugation and incubated
with AnnexinV-FITC (Life Technologies, Carlsbad, CA V13245, USA,) and 7-AAD (Becton Dickinson,
Franklin Lakes, NJ 555815, USA). Cell suspensions were analyzed with an Attune Acoustic Focusing
Flow Cytometer (Applied Biosystems). Cell death by apoptosis was scored by quantifying the
population of AnnexinV-FITC-positive cells using FlowJo version 10 software.
2.3. Western Blot
Riva WT and VR cells were washed with phosphate-buffered saline and incubated at 4 ◦C
with lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol,
1% Triton-X-100 and 1 tablet of complete EDTA-free protease inhibitor (Thermo Scientific, Brussels,
Belgium)) for 30 min. Cell lysates were centrifuged for 5 min at 4000× g and analyzed by Western
blotting as previously described [21]. Western blot quantification was done using Image Lab 5.2
software (Bio-Rad Laboratories, Temse, Belgium).
2.4. Intracellular Ca2+ Measurement in Intact Cells
Riva VR and WT cells were loaded with 1 µM Fura-2-AM (Eurogentec, Seraing, Belgium) at room
temperature in modified Krebs solution (150 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 11.6 mM HEPES
(pH 7.3), 11.5 mM glucose and 1.5 mM CaCl2) for 30 min. This was followed by a de-esterification
step in the absence of extracellular Fura-2-AM for 30 min at room temperature. Extracellular Ca2+
was chelated with EGTA before stimulating cells with IgG/IgM (12 µg/mL; Jackson ImmunoResearch
Europe Ltd., Cambridge, UK) to elicit intracellular Ca2+ signaling. Alternatively, thapsigargin (1 µM),
an inhibitor of SERCA, was used to deplete the ER to gauge ER Ca2+ content. Fluorescence was
monitored using a Flexstation 3 microplate reader (Molecular Devices, Sunnyvale, CA, USA) by
alternating the excitation of Fura-2 at 340 and 380 nm and collecting the emission at 510 nm. All traces
are shown as the ratio of emitted fluorescence of Fura-2 (F340/F380). GraphPad Prism 8 was used to
calculate area under the curve (AUC).
2.5. siRNA Transfection of Riva VR Cells
Riva VR cells were transfected using the Amaxa® Cell Line Nucleofector® Kit L (Lonza, Basel,
Switzerland), program C-05, as described in Bittremieux et al. [29]. Briefly, 3 × 106 cells were transfected
with 500 nM siCTRL (ON-TARGET plus, non-targeting control pool, from Dharmacon) and 500 nM
siBcl-XL (hs.Ri.BCL2L1.13.1, from IDT). At 24 h post-transfection, the cells were used for experiments
and collected for Western blot analysis to confirm knockdown of Bcl-XL.
3. Results
3.1. Characterization of the Venetoclax-Sensitive and -Resistant Riva Cells
To obtain venetoclax-resistant Riva cells (Riva VR), parental Riva cells (Riva WT) were chronically
exposed to increasing concentrations of venetoclax. A dose–response experiment indicated approximately
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a tenfold difference in venetoclax sensitivity as demonstrated by the different EC50 values for venetoclax
(Figure 1a,b) derived from FACS measurements (AnnexinV-7-AAD staining). Thus, these data confirm
the presence of venetoclax resistance in the VR cell line relative to the parental cell line.
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population was defined as the AnnexinV-FITC-positive fraction. Data presented are average ± SEM 
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sensitivity of DLBCL cells with IP3R2-expression levels [28], we compared the expression of IP3R2 
and the other IP3R isoforms between Riva WT and Riva VR. Yet, consistent with the findings that 
Riva VR cells were not more sensitive to BIRD-2 than Riva WT cells, IP3R2-expression levels were 
very similar between Riva WT and Riva VR cells (Figure 2b). Similarly, the expression levels of the 
other isoforms of the IP3R (IP3R1 and -3) were not different between Riva WT and Riva VR cells 
(Figure 2b). These data demonstrate that cancer cells with acquired venetoclax resistance do not 
become dependent on Bcl-2’s non-canonical role at the ER for survival. 
Figure 1. Riva VR cells are resistant to venetoclax as compared to Riva WT cells. (a) Representative
dot plots from flow cytometric analysis of AnnexinV-FITC/7-AAD stained Riva wild-type (WT) and
venetoclax-resistant (VR) cells, treated with venetoclax at 3 nM and 100 nM, respectively, during 24 h.
(b) Dose–response curves of Riva WT and Riva VR 24 h after drug exposure. The apoptotic population
was defined as the AnnexinV-FITC-positive fraction. Data prese ted are average ± SEM (n = 5).
3.2. Acquired Venetoclax Resistance does not Induce Increased Sensitivity Towards BIRD-2
Previous work performed by our lab [30] revealed an inverse correlation between venetoclax and
BIRD-2 sensitivity in DLBCL cell lines. Based on these findings, we hypothesized that the cells with
acquired resistance to venetoclax could have become more susceptible to BIRD-2, illus r ing a shift
from Bcl-2’s relianc on the hydroph bic cleft tow rds a BH4 domain-d endent mechanism. However,
a do e–response expe iment showed no significant difference in the EC50 values of BIRD-2 in Riva VR
compared to Riva WT (Figure 2a). As in previous work where we associated BIRD-2 sensitivity of
DLBCL cells with IP3R2-expression levels [28], we compared the expression of IP3R2 and the other
IP3R isoforms between Riva WT and Riva VR. Yet, consistent with the findings that Riva VR cells were
not more sensitive to BIRD-2 than Riva WT cells, IP3R2-expression levels were very similar between
Riva WT and Riva VR cells (Figure 2b). Similarly, the expression levels of the other isoforms of the
IP3R (IP3R1 and -3) were not different between Riva WT and Riva VR cells (Figure 2b). These data
demonstrate that cancer cells with acquired venetoclax resistance do not become dependent on Bcl-2’s
non-canonical role at the ER for survival.
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Figure 2. Riva WT and VR cells have a similar sensitivity towards BIRD-2 treatment. (a) Dose–response
curves of Riva WT and VR cells after incubation with BIRD-2 for 24 h. The apoptotic population
was defined as the AnnexinV-FITC-positive fraction. Data presented are average ± SEM (n = 5).
(b) Representative Western blots of IP3R1, 2 and 3-expression levels in Riva WT and Riva VR cells.
GAPDH was used as a loading control. Quantification of IP3R1, -2 and -3-protein levels in Riva WT
and Riva VR cells. For each blot, the immunoreactive bands were quantified and normalized towards
the signal obtained for Riva WT cells, which was set at 1. Data are presented as average ± SD (n ≥ 7).
3.3. IgG/IgM-Induced Cytosolic Ca2+ Signaling and ER Store Content Do not Differ between Riva WT and
Riva VR
Since we observed that IP3R levels were unchanged, we wondered whether Ca2+ handling in
Riva WT and Riva VR was also unaltered. To this end, we conducted cytosolic Ca2+ measurements by
loading the cells with Fura-2-AM. Cytosolic Ca2+ signals were triggered by the addition of IgG/IgM
(12 µg/mL) in the presence of 3 mM EGTA, an extracellular Ca2+-chelating agent (Figure 3a). The latter
ensures that only Ca2+ release from intracellular Ca2+ stores occurs without Ca2+ influx. The cytosolic
Ca2+ signals elicited by B-cell receptor stimulation via IgG/IgM were very similar between Riva WT
and Riva VR, as is evident from the area under the curve (AUC) (Figure 3b). Furthermore, we used
thapsigargin (1 µM) to indirectly quantify the ER Ca2+ store content. However, no significant difference
was observed in the thapsigargin-releas ble Ca2+ pool between Riva WT and Ri a VR, indicating that
Ca2+ l vels present in the ER of Riv VR cells and of Riva WT were very sim l r (Figure 3c).
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Figure 3. Cytosolic IgG/IgM Ca2+ responses and ER Ca2+ content do not differ between Riva WT
and Riva VR. (a) Typical cytosolic Ca2+ traces in Fura-2-AM-loaded Riva WT and VR. Sixty seconds
after the chelation of extracellular Ca2+ with EGTA (3 mM), the cells were stimulated with vehicle or
12 µg/mL IgG/IgM to provoke a cytosolic Ca2+ signal. (b) Analysis of the area under the curve (AUC)
of the IgG/IgM-triggered peak. Data are presented as average ± SEM (N = 5). (c) Cytosolic Ca2+ traces
in Fura-2-A -loaded Riva T (black) and VR (red). Sixty seconds after the chelation of extracellular
Ca2+ with EGTA (3 mM), the cells were treated ith thapsigargin (1 µ ) to deplete ER Ca2+ stores.
Data re present d as verage ± SEM (N = ).
3.4. Acquired Venetoclax Resistance Is Associated with Bcl-XL Upregulation and Bcl-XL Dependence
Next, we decided to check the levels of selected Bcl-2 protein family members via Western blot,
since they are known to be involved in venetoclax resistance [32,33]. While cl-1 le els ere si ilar in
Riva WT nd Riva VR cells, a significant i creas in Bcl-XL-protein levels was observed in i in
the Western blots (Figure 4a). To investiga e whet r Bcl-XL upregulation was indeed responsible for
the induced ven toclax resistance, we treated both Riva WT and Riva V cells with a panel of validated
on-target BH3-mim tic Bcl-2-family inhibitors: venetoclax (10 nM and 300 nM), a selective Bcl-XL
inhibitor A-1155463 (1 µM and 3 µM) and a selective Mcl-1 inhibitor S63845 (1 µM and 10 µM) [34].
As confirmed before, Riva WT and Riva VR displayed a large difference in sensitivity towards
venetoclax (Figure 4b). Excitingly, the venetoclax resistance could be overcome by simultaneously
treating the cells with venetoclax (10 nM) and the Bcl-XL inhibitor A-1155463 (1 µM). It is interesting
to note that 1 µM of A-1155463 did not provoke cell death when administered alone. Additionally,
both Riva WT and VR were sensitive to this compound at higher concentrations (3 µM), pointing to a
pre-existing susceptibility to the inhibition of Bcl-XL. However, Bcl-XL inhibition by itself was much
less potent in killing the cells than combined Bcl-XL/Bcl-2 inhibition. This illustrates that even though
Riva VR cells seemed to become more dependent on Bcl-XL when treated with venetoclax, they did
not lose the ability to block cell death via Bcl-2. Inhibition of Mcl-1’s hydrophobic cleft did not restore
venetoclax sensitivity (Figure 4b). These data may indicate that Bcl-XL upregulation contributes to the
survival of Riva c lls after chronic ex osure to venetoclax. Furthermore, this illustrates that Riva VR
cells achieve a status of dual dependency on Bcl-2 and Bcl-XL, but not on Mcl-1.
Biomolecules 2020, 10, 1081 7 of 13Biomolecules 20, 10, x FOR PEER REVIEW 7 of 13 
 
Figure 4. Bcl-XL-expression levels are upregulated in Riva VR cells. (a) Left: representative Western 
blots of Bcl-XL-, Mcl-1- and Bcl-2-expression levels in Riva WT and VR cells. Vinculin was used as a 
loading control. Right: quantification of Bcl-XL-, Mcl-1- and Bcl-2-expression levels. Expression levels 
in Riva VR were normalized on Riva WT, which was set at 1. Data are presented as the average ± SD 
(n ≥ 7); ** p < 0.01. (b) Flow cytometric analysis of AnnexinV-FITC negative and 7-AAD negative cells 
treated with BH3-mimetic inhibitors of Bcl-XL (A-1155463), Mcl-1 (S63845) and Bcl-2 (venetoclax) for 
24 h. Data are represented as mean ± SD (n = 5); * p < 0.05, **** p < 0.001. 
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To further corroborate these findings, we used a siRNA-mediated knockdown approach to 
decrease the expression levels of Bcl-XL in Riva VR cells. Western blot analysis validated that siBcl-
XL could reduce Bcl-XL-protein levels in Riva VR cells (Figure 5a). Furthermore, cell death analysis 
in Riva VR cells treated with siCTRL or siBcl-XL revealed that knockdown of Bcl-XL sensitized the 
cells to venetoclax (300 nM) (Figure 5b). In addition, Riva WT and VR cells were treated with ABT-
737, a non-selective BH3 mimetic inhibitor of both Bcl-2 and Bcl-XL [35]. While Riva VR cells are 
much more resistant to venetoclax than Riva WT cells, Riva VR and Riva WT seemed equally sensitive 
to ABT-737 (Figure 5c). Both experiments underpin our hypothesis that the resistance of Riva VR cells 
towards venetolax is at least in part due to upregulation of Bcl-XL. 
Figure 4. Bcl-XL-expression levels are upregulated in Riva VR cells. (a) Left: representative Western
blots of Bcl-XL-, Mcl-1- and Bcl-2-expression levels in Riva WT and VR cells. Vinculin was used as a
loading control. Right: quantification of Bcl-XL-, Mcl-1- and Bcl-2-expression levels. Expression levels
in Riva VR were normalized on Riva WT, which was set at 1. Data are presented as the average ± SD
(n ≥ 7); ** p < 0.01. (b) Flow cytometric analysis of AnnexinV-FITC negative and 7-AAD negative cells
treated with BH3-mimetic inhibitors of Bcl-XL (A-1155463), Mcl-1 (S63845) and Bcl-2 (venetoclax) for
24 h. Data are represented as mean ± SD (n = 5); * p < 0.05, **** p < 0.001.
3.5. Knockdown of Bcl-XL Resensitizes Riva VR Cells to Venetoclax
To further corroborate these findings, we used a siRNA-mediated knockdown approach to
decrease the expression levels of Bcl-XL in Riva VR cells. Western blot analysis validated that siBcl-XL
could reduce Bcl-XL-protein levels in Riva VR cells (Figure 5a). Furthermore, cell death analysis in
Riva VR cells treated with siCTRL or siBcl-XL revealed that knockdown of Bcl-XL sensitized the cells
to venetoclax (300 nM) (Figure 5b). In addition, Riva WT and VR cells were treated with ABT-737, a
non-selective BH3 mimetic inhibitor of both Bcl-2 and Bcl-XL [35]. While Riva VR cells are much more
resistant to venetoclax than Riva WT cells, Riva VR and Riva WT seemed equally sensitive to ABT-737
(Figure 5c). Both experiments underpin our hypothesis that the resistanc of Riva V cells towards
venetolax is at least in part due to upregulation of Bcl-XL.
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Figure 5. Bcl-XL knockdown sensitizes Riva VR cells to venetoclax. (a) Left: representative Western
blots of Bcl-XL-expression levels in Riva VR cells after treatment with siCTRL or siBcl-XL. β-actin
was used as a loading control. Right: quantification of Bcl-XL-expression levels. Expression levels in
Riva VR were normalized to the Bcl-XL levels in siCTRL-treated cells, which were set at 1. Data are
represented as the average ± SD (n = 3). (b) Flow cytometric analysis of AnnexinV-FITC negative and
7-AAD negative cells treated with venetoclax for 24 h. Data are ± SD (N = 3); * p < 0.05. (c) Flow
cytometric analysis of AnnexinV-FITC negative and 7-AAD negative Riva WT and VR cells treated
with ABT-737 for 24 h. Data are ± SD (n = 3); * p < 0.05, ** p < 0.01.
3.6. Acquired Venetoclax Resistance in Riva Cells Generates Cross-Resistance for BDA-366
Finally, we also assessed the sensitivity towards another presumed BH4-domain inhibitor of Bcl-2,
BDA-366 [31]. This small molecule was identified from a screen for BH4-domain-interacting molecules
and is thought to switch Bcl-2 into a pro-apoptotic protein by triggering surface exposure of its BH3
domain [36]. However, recent work has cast some doubts on whether BDA-366 is a bona fide Bcl-2
inhibitor [34]. Indeed, when Riva WT and Riva VR cells were treated with BDA-366 in a dose–response
experiment, Riva WT cells were approximately ten times more sensitive to the compound than Riva
VR cells (Figure 6). This indicates that induction of venetoclax resistance also results in resistance
against BDA-366.
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4. Discussion
The launch of venetoclax in the clinic to combat CLL has been a relative success [11]. While this
molecule improved the treatment of patients with CLL, some patients develop resistance against
venetoclax very quickly [11]. Thus, it is important to elucidate the mechanisms underlying venetoclax
resistance and to develop strategies for killing such venetoclax-resistant cancer cells. To this end, we
compared the DLBCL cell line Riva before and after chronic venetoclax exposure. By treating the cells
for a longer time with venetoclax, they become resistant to it. In this way we are able to study the
mechanisms involved in venetoclax resistance.
As we previously showed that there was a reciprocal sensitivity among a collection of DLBCL
cells between BIRD-2 and venetoclax [30], we were interested to assess whether DLBCL cells with
acquired resistance towards venetoclax could have become sensitized towards BIRD-2. However, our
data revealed that venetoclax resistance did not shift Bcl-2’s anti-apoptotic function from dependency
on the hydrophobic cleft to using its BH4 domain to suppress cell death. Indeed, both cell lines
displayed similar sensitivities to BIRD-2, a BH4 domain targeting peptide, and Riva VR did not show
an upregulation of IP3R2-protein levels, a parameter shown to correlate with BIRD-2 sensitivity in
previous work [28]. We did not observe any differences in IP3R expression levels and neither in
IgG/IgM-induced cytosolic Ca2+ signaling.
Instead, we observed an upregulation of anti-apoptotic Bcl-2 family member Bcl-XL in Riva VR
cells compared to regular Riva cells. We demonstrated that this Bcl-XL upregulation contributed to
venetoclax resistance, since siRNA-mediated knockdown of Bcl-XL in Riva VR cells could sensitize
these cells to venetoclax. Consequently, the venetoclax resistance of Riva VR cells could be overcome
by validated BH3-mimetic drugs [34], such as A-1155463, a selective antagonist of Bcl-XL or ABT-737, a
non-selective Bcl-2/Bcl-XL inhibitor. Upregulation of Bcl-XL, in cooperation with Mcl-1, is a resistance
mechanism that has previously been reported for other DLBCL cell models, such as SU-DHL-6,
OCI-LY-19 and OCI-LY-1 [33,37]. Venetoclax resistance in OCI-LY-1 cells (as well as CLL patient cells)
was also accompanied by a remodeling of the mitochondrial metabolism involving activation of AMPK
and increased OXPHOS [33].
Interestingly, Riva VR cells seem to develop a dual dependency on Bcl-2 family members, since
inhibiting Bcl-XL alone is not sufficient to completely kill Riva VR cells. This shows that while Bcl-XL
upregulation may contribute to acquiring resistance against venetoclax, Riva VR cells do not shift
away from using Bcl-2 as an anti-apoptotic buffer. It has been reported that different members of the
Bcl-2 protein family have different affinities for their pro-apoptotic counterpart [38]. Yet, functional
redundancy of Bcl-2-protein family members has been described [39,40]. Our findings are in line
with this concept, rendering it more challenging to target a single Bcl-2 family member for prolonged
treatment of cancer due to compensatory upregulation of other Bcl-2 family members providing drug
resistance. In this study, we did not examine the mechanism by which Bcl-XL is upregulated in Riva
VR. A previous study in B-cell lymphoid cell models, however, revealed downregulation of miR-377, a
microRNA suppressing Bcl-XL expression, in venetoclax-resistant cell models [41].
Furthermore, our data suggest that venetoclax resistance may generate cross-resistance to other
molecules that presumably target Bcl-2, such as BDA-366. BDA-366 is proposed to target Bcl-2’s BH4
domain and turn Bcl-2 into a pro-apoptotic protein [31,36]. Thus, while BDA-366 and venetoclax
inhibit Bcl-2 via distinct mechanisms, cancer cells that acquire resistance against venetoclax also seem
to acquire resistance against BDA-366. Yet, it should be noted that recent work of the Letai group
has questioned BDA-366 as an on-target inhibitor of Bcl-2 proteins [34], indicating that BDA-366 can
kill cancer cells independently of Bcl-2. Thus, the results obtained with BDA-366 may need to be
interpreted with care in relation to BH4-domain antagonism.
Different mechanisms for venetoclax resistance have been described in different types of
cancer [32,37,42–44]. Beyond upregulation of other anti-apoptotic Bcl-2-family members that are
not inhibited by venetoclax, Bcl-2 mutations have emerged in CLL patients undergoing venetoclax
treatment. A paired analysis of pre-venetoclax and venetoclax progression in 15 CLL patients revealed
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a de novo Bcl-2 mutation, changing residue Gly101 in Val in 7 CLL patients [32]. Bcl-2G101V displayed
a severely reduced affinity for binding venetoclax. This rendered the drug inefficient in disrupting
Bcl-2’s association with pro-apoptotic family members and enabled cancer cell resistance towards
venetoclax. In follow-up work, it was shown that Bcl-2 mutations were frequently occurring in
CLL patients receiving venetoclax, including mutations at other residues such as Asp103Tyr [42].
More recently, several other Bcl-2 mutations have been identified to co-occur with Gly101Val, whereby
several patients accumulated multiple Bcl-2 mutations [45]. From the latter study, it is clear that
different venetoclax-resistance mechanisms can arise, including the upregulation of Bcl-XL. In addition,
cancer cells may remodel signaling pathways to elicit resistance against chemotherapy. For example,
upregulation of Akt activity was associated with venetoclax resistance and severely reduced Bcl-2 and
Bim expression levels [46]. Interestingly, in the same vein, kinase inhibitors were found to be effective to
overcome venetoclax resistance, possibly interfering with kinase-mediated responses and subsequent
remodeling caused by signaling cues from the microenvironment [47]. A similar mechanism was
found in primary patient samples of DLBCL [48].
On a more profound level, it is interesting to ask whether certain cancer cells are “primed” to
follow a predetermined path towards resistance. If that were the case, would Riva cells consequently
upregulate Bcl-XL in response to chronic venetoclax exposure, or would a different resistance mechanism
develop? There may be factors underlying this response, and identification of these factors would allow
for a prediction of possible venetoclax resistance in patients. If the resistance occurs by coincidence, it
is important to identify the parameters setting out the path towards resistance.
5. Conclusions
Venetoclax resistance has emerged as a complicating factor for the prolonged treatment of CLL
patients with the drug, limiting long-term therapeutic success in the clinic. Therefore, strategies to
overcome cancer cell resistance to venetoclax are highly needed. Since venetoclax is investigated as
a potential drug against DLBCL, we anticipate similar problems in the treatment of these patients.
Using an isogenic DLBCL cell model with high and low venetoclax sensitivity, we found that Bcl-XL is
upregulated in venetoclax-resistant cells, while the cells do not become more sensitive to BIRD-2, a
peptide that disrupts IP3R/Bcl-2 complexes and disrupts Bcl-2’s function at the ER. Similarly, venetoclax
resistance seems to induce cross-resistance towards BDA-366, a small molecule reported to target
the Bcl-2 BH4 domain. Therefore, Bcl-XL upregulation is a factor that cancer cells exploit to acquire
resistance towards venetoclax and which may be seized upon to improve the treatment of cancer
patients that lose responsiveness towards venetoclax treatment.
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